UK approves oral GLP-1 pill for obesity and diabetes

UK regulators have authorised an oral GLP-1 medicine for the treatment of obesity and type 2 diabetes, officials said. They described the decision by the Medicines and Healthcare products Regulatory Agency (MHRA) as Europe’s first approval for an oral GLP-1 of this kind.

Following MHRA clearance, officials said the product can be prescribed through private routes. They added that broader use through the public health service for weight management will hinge on a separate evaluation process, leaving the timing and scale of publicly funded access for obesity uncertain.

Two access routes: diabetes approval versus obesity funding review Officials said the medicine is already approved for Officials said the medicine is already approved for immediate use within the NHS for managing type 2 diabetes. That means patients with type 2 diabetes can access the oral GLP-1 through established NHS pathways tied to the diabetes indication. For weight management, officials outlined a different route that depends not only on regulatory authorisation but also on decisions about public funding. They said the manufacturer plans to apply to the Institute for Health and Care Excellence (NICE) to seek public funding for the weight-management indication. Until NICE completes its assessment, officials said NHS availability for obesity treatment remains unresolved. They also highlighted that this two-track system—regulatory clearance on one side and health-technology assessment on the other—can result in different patient experiences during the interim.

Clinical use and evidence cited by officials

Officials pointed to clinical data referenced in the Officials pointed to clinical data referenced in the announcement indicating the tablet can help people maintain weight after stopping injectable GLP-1 treatments. They framed the oral form as an option that could be considered when clinicians and patients are weighing injections against other formats, including when treatment plans change over time. Officials also said the medicine is expected to be used alongside lifestyle measures to achieve intended outcomes. They described the next steps for the weight-management indication as separate from the MHRA authorisation, because the decision on NHS funding for obesity treatment sits with the NICE-linked process. Operational considerations and side effects Officials said a tablet format could offer practical advantages compared with injectable GLP-1 medicines. They added that an oral option may reduce logistical hurdles tied to injections, which they said can influence adherence for some patients.

At the same time, officials said gastrointestinal side effects have been associated with the medicine, including nausea and vomiting. They said these effects, together with the need for continued lifestyle interventions, are among the factors clinicians and patients typically weigh when starting therapy and when deciding whether to continue.

Officials said the MHRA authorisation adds another option to the UK’s approach to treating obesity and type 2 diabetes. For obesity treatment within the NHS, however, officials underscored that the central uncertainty is the outcome of the NICE review, which will shape real-world rollout of publicly funded access.